9-ING-41 + nab-paclitaxel + gemcitabine

**9-ING-41 + nab-paclitaxel + gemcitabine** is a combination regimen under clinical investigation for advanced solid tumors, especially pancreatic cancer. - **9-ING-41** is a first-in-class, intravenously administered small molecule inhibitor of glycogen synthase kinase-3 beta (GSK-3β), a serine/threonine kinase implicated in cancer cell proliferation and survival. It inhibits tumor growth by downregulating the NF-κB pathway and suppressing the expression of several pro-survival and cell cycle regulatory genes. The mechanism includes induction of apoptosis and cell cycle arrest at various checkpoints[1][3][5]. - **Nab-paclitaxel** is albumin-bound paclitaxel, a microtubule inhibitor, facilitating drug delivery to tumors due to the albumin carrier, and is approved for use in combination with gemcitabine for metastatic pancreatic cancer[4]. - **Gemcitabine** is a nucleoside analog that interferes with DNA synthesis, resulting in cell death, commonly used in solid tumors including pancreatic cancer[4]. This combination is in clinical trials for patients with advanced solid tumors, particularly metastatic or locally advanced pancreatic cancer, based on synergistic preclinical antitumor activity and improved chemotherapy response observed in preclinical and early-phase studies[3].

Other names

albumin-bound paclitaxelpaclitaxel albumin-bound